Michael Reusch
Overview
Explore the profile of Michael Reusch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nordstrom J, Wennberg L, Nowak G, Larsson T, Thuresson S, Reusch M
Transplant Direct
. 2024 Nov;
10(12):e1727.
PMID: 39534758
Background: RMC-035 is a modified version of alpha-1-microglobulin, an endogenous protein developed as a renoprotective agent. Its intended use is to reduce the risk of irreversible loss of kidney function...
2.
Zarbock A, Larsson T, Noiseux N, Mazer C, Bohm J, Laflamme M, et al.
EClinicalMedicine
. 2024 Sep;
76:102830.
PMID: 39318788
Background: Cardiac surgery invariably triggers acute kidney stress causing adverse renal outcomes. The AKITA study evaluated the efficacy and safety of RMC-035, a novel analogue of alpha-1-microglobulin, for reducing cardiac...
3.
Ganz T, Locatelli F, Arici M, Akizawa T, Reusch M
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445252
Roxadustat is a novel agent with a distinct mechanism of action compared to erythropoiesis-stimulating agents (ESAs) and a potentially different combination of effects on iron parameters. This narrative review describes...
4.
Barratt J, Dellanna F, Portoles J, Choukroun G, De Nicola L, Young J, et al.
Adv Ther
. 2023 Feb;
40(4):1546-1559.
PMID: 36749544
Introduction: This study was conducted to elucidate the safety of roxadustat, an oral medication, in patients with non-dialysis-dependent (NDD) or incident dialysis dialysis-dependent (ID-DD) chronic kidney disease (CKD). Methods: Safety...
5.
Sepah Y, Nguyen Q, Yamaguchi Y, Otsuka T, Majikawa Y, Reusch M, et al.
Kidney Int Rep
. 2022 May;
7(4):763-775.
PMID: 35497806
Introduction: Roxadustat is an orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that represents a novel therapeutic option for patients with anemia of chronic kidney disease (CKD). Methods: Conducted in...
6.
Barratt J, Andric B, Tataradze A, Schomig M, Reusch M, Valluri U, et al.
Nephrol Dial Transplant
. 2022 Feb;
37(4):805.
PMID: 35146511
No abstract available.
7.
Csiky B, Schomig M, Esposito C, Barratt J, Reusch M, Valluri U, et al.
Adv Ther
. 2021 Sep;
38(10):5361-5380.
PMID: 34537926
Introduction: Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled...
8.
Barratt J, Sulowicz W, Schomig M, Esposito C, Reusch M, Young J, et al.
Adv Ther
. 2021 Sep;
38(10):5345-5360.
PMID: 34523074
Introduction: This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods: Efficacy and safety results from four phase 3, randomized,...
9.
Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M
Kidney Int Rep
. 2021 Jul;
6(7):1810-1828.
PMID: 34307976
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease...
10.
Barratt J, Andric B, Tataradze A, Schomig M, Reusch M, Valluri U, et al.
Nephrol Dial Transplant
. 2021 Jun;
36(9):1616-1628.
PMID: 34077510
Background: Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). Methods: This randomized, open-label, active-controlled Phase 3 study...